Definium Therapeutics stock
DFTXNASDAQDefinium Therapeutics, Inc., HealthcareISIN CA24477V1058
41Score 41 out of 100, Weak
Price and trend
72 / 100
Price history
+176% in one yearThe chart shows daily closes over 10 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 14% above it.
Since June 2025 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 46).
The price is 29% below its 52-week high. Largest decline in 10 years: 100% (March 2017 to December 2019).
Chart figures for advanced users
- SMA 50$36.31
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$30.27
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)46
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$10.68
- The lowest closing price of the last twelve months.
- Resistance$48.45
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Definium Therapeutics, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $4.63B, is number 80 of 296 companies in its industry on MEQIRI.
- MEQIRI Score 41 out of 100 (Weak): rank 538 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $411.59M, financial debt $40.39M (debt as of 30 Sep 2025).Stability 54
Weaknesses
- DilutionShare count up 403% since 2020.Capital allocation 18
- Loss-makingLoss of $183.79M over the last 12 months.Fundamentals 17
- Negative free cash flowFree cash flow −$131.56M over the last 12 months.Fundamentals 17
Its standout strengths are momentum and technical analysis, while fundamentals and profitability hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredNo fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 0%, operating 0%, net 0%.
Debt & balance sheet
latest quarterDebt is low, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 25 Feb 2027in 105 days
- Last reported
- 9 Nov 2026EPS reported −$0.46 (expected −$0.56)above expectations
Analyst estimates
Analysts have raised their 2026 earnings estimate by 5.2% since 15 Oct 2026.
- Earnings per share
- −$3.02+5.2%
- Revenue
- $0
- Earnings per share
- −$1.99+2.6%
- Revenue
- $29.35M0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: −5.8%Timeline for phase III data confirmed: Emerge this quarter, Voyage early and Panorama late in the third quarter.
“Our lead program, DT120 ODT, is advancing with 4 ongoing Phase III studies across major depressive disorder, or MDD, and generalized anxiety disorder, or GAD, with top line data from Emerge expected later this quarter, followed by Voyage and Panorama in the third quarter.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 7 May 2026 (fiscal Q1 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 5 insiders sold, $5.64M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Karlin DanielSale
25 Sept 2026, Chief Medical Officer
- Shares
- 10,853
- Price
- $36.57
- Value
- $396,894
- Barrow RobertSale
25 Sept 2026, Chief Executive Officer
- Shares
- 31,550
- Price
- $36.57
- Value
- $1.15M
- Wiley Matthew T.Sale
25 Sept 2026, Chief Commercial Officer
- Shares
- 3,097
- Price
- $36.57
- Value
- $113,257
Show 8 more
- Sullivan MarkSale
25 Sept 2026, Chief Legal Officer
- Shares
- 14,051
- Price
- $36.57
- Value
- $513,845
- Roberts BrandiSale
25 Sept 2026, Chief Financial Officer
- Shares
- 3,377
- Price
- $36.57
- Value
- $123,497
- Barrow RobertSale
3 Sept 2026, Chief Executive Officer
- Shares
- 19,023
- Price
- $37.94
- Value
- $721,733
- Sullivan MarkSale
25 Jun 2026, Chief Legal Officer
- Shares
- 13,008
- Price
- $45.03
- Value
- $585,750
- Roberts BrandiSale
25 Jun 2026, Chief Financial Officer
- Shares
- 3,013
- Price
- $45.03
- Value
- $135,675
- Barrow RobertSale
25 Jun 2026, Chief Executive Officer
- Shares
- 29,208
- Price
- $45.03
- Value
- $1.32M
- Karlin DanielSale
25 Jun 2026, Chief Medical Officer
- Shares
- 10,035
- Price
- $45.03
- Value
- $451,876
- Wiley Matthew T.Sale
25 Jun 2026, Chief Commercial Officer
- Shares
- 2,867
- Price
- $45.03
- Value
- $129,101
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Definium Therapeutics
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 41
- Sector median
- 53
Categories against the sector medianMedian of 714 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Dianthus TherapeuticsDNTH $5.03B46
- Travere TherapeuticsTVTX $5B50
- Adaptive BiotechnologiesADPT $4.85B47
- Ionis PharmaceuticalsIONS $4.72B32
- CRISPR TherapeuticsCRSP $4.44B37
- CamurusCAMX.ST $4.42B74
- Relay TherapeuticsRLAY $4.36B46
- Tango TherapeuticsTNGX $4.34B45
ETFs that hold Definium Therapeutics
Held by 6 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.27% | 0.35% | €1.21B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.09% | 0.43% | €2.48B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.06% | 0.35% | €434.1M |
Show 3 more
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.03% | 0.35% | €8.19B |
| Vanguard ESG Global All Cap UCITS ETF (USD) AccumulatingV3AA | 0.01% | 0.24% | €1.69B |
| Vanguard FTSE Global All-Cap UCITS ETF Accum USDVGLA | 0.00% | 0.07% | €3.9B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 30 Nov 2017)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.